Reported 2 days ago
The FDA has officially declared the end of the drug shortage for Eli Lilly's GLP-1 products, including tirzepatide, following pressures from compounders and an ongoing lawsuit. This decision may lead to copycat manufacturers halting production within 60 days. Meanwhile, Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, are also expected to come off the shortage list soon, as both companies focus on meeting heightened demand while enforcing patent protections.
Source: YAHOO